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Abstract
The search for new pharmacologically active agents obtained by screening natural sources such as plant (or marine) extracts and microbial fermentations has led to the discovery of many clinically active drugs that play a major role in the treatment of human diseases. In spite of the fact that, at present we have at our command a formidable array of modern drugs, the need to discover and invent new agents is genuine and urgent. It has been estimated that satisfactory therapy is available for about one third of all presently known human ailments, and diseases, such as cancer, AIDS, autoimmune diseases, to mention just a few, continue to evade reasonable solution. 
Since ages, natural substances are being used as the sources of drugs. The plants not only continue to retain their historical significance as important sources for development of new drugs, but also are extremely useful as sources of lead compounds for structural modification and optimization that can also be employed as specific probes in biochemical studies. Plant derived compounds which have recently undergone development include the anticancer agents such as taxol and camptothecin, the antimalarial drug artemisinin and Indian Ayurvedic drug forskolin etc. 
Recently, emerging approaches such as advanced spectral techniques, combinatorial chemistry, computer assisted drug design and high-throughput screening has significantly reinforced the lead compound generation and drug discovery processes. Inspired by the trends in the modern phytochemical research, the author has made a modest effort to investigate on some folklore medicinal plants, for which scanty reports are available. Chemical investigation of the selected plants led to the isolation of 24 secondary metabolites, out of which 8 are new, and these are described in chapters I and II, while screening for selected biological activities are reported in chapter III. 

Chapter-I 
The wide spread genus Euphorbia is the source of a large number of biologically active compounds. The diterpenes were the first group of compounds isolated from the genus Euphorbia. Besides the well-known skin irritant and tumor promoting diterpenes, considerable attention has recently been paid to the macrocyclic diterpenes because of their high chemical diversity and therapeutically relevant bioactivity. 
The previous literature on ingol diterpenes along with a brief description of the classification and biosynthesis of diterpenes from the genus Euphorbia has been discussed in view of the isolation of novel ingol diterpenes from E. nivilia, whose structural studies are also explained in this chapter. 
Chemical investigation of methanol extract of the plant Euphorbia nivulia afforded nine compounds EN-1 to EN-9 of which, eight compounds were ingol diterpenes (EN-2 to EN-9) and the other compound was a known cycloartane derived triterpene, cycloeucalenol (EN-1). The details of the extraction and isolation of the compounds from the plant material were described in the experimental section. The five compounds EN-5 to EN-9 are found to be the new ingol diterpenes, compound EN-3 is the first time report of the isolation from plant source (earlier reported as a derivative) and the other two compounds (EN-2 and EN-4) are first time isolated from this plant. The following compounds are isolated from the plant E. nivulia. EN-1: Cycloeucalenol. EN-2: 3,12-diacetyl-8-methoxyl-7-angeloylingol. EN-3: 12-acetyl-7-angeloyl-8-methoxylingol. EN-4: 3,7,12-triacetyl-8-benzoylingol. EN-5: 3,12-diacetyl-8-benzoylingol. EN-6: 3,12-diacetyl-7-benzoyl-8-nicotinylingol. EN-7: 3,12-diacetyl-8-methoxylingol. EN-8: 3-acetyl-8-methoxyl-7-angolyl-12-hydroxylingol. EN-9: 3,12-diacetyl-7-angolyl-8-hydroxylingol. 
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Chapter II deals with the extraction, isolation and characterization of the secondary metabolites from the plants Lepidagathis cristata, Cassine glauca, Phyla nodiflora and Elytraria acaulis. All these plants as a whole plant extract or in combination with some other plant extracts were found to treat certain disorders (mainly as anti-inflammatory) in the tribal areas of Bhadrachalam forest region, Andhra Pradesh. The literature survey on these four plants is given in the introduction part of this chapter. 
Chemical investigation of ethyl acetate extract of the whole plant Lepidagathis cristata yielded three compounds LC-1, LC-2 and LC-3. Compound LC-1 was found to be a mixture of four sterols from its acetylated product's GC mass spectrum. The other two compounds LC-2 and LC-3 were found to be the new compounds. Their structures were confirmed from the extensive NMR spectroscopic data. LC-2 : Docosyl-(E)-ferrulate LC-3 : CristatinA (cyclo-alanyl-6,7-disiopentenyl-2-(1?,1?-dimethylallyl-8- (Z)-ene-tryptophan) Figure (​http:​/​​/​www.csirexplorations.com​/​images_et​/​a74_figureNO41.jpg" \t "_blank​) 
Chemical investigation of both the ethyl acetate and methanol extracts of the plant Cassine glauca yielded eight compounds CG-1 to CG-8. Compound CG-6 was isolated from methanol extract and the remaining compounds were isolated from EtOAc extract. The compounds CG-1 to CG-7 were first time isolated from this plant and CG-8 is a new compound. Extensive NMR (1D & 2D) and mass spectral data revealed that the compounds CG-1 to CG-5 to be the triterpenes, CG-6 to be a flavan derivative, and CG-7 & CG-8 to be two sesquiterpenes. CG-1 : Pristimerin CG-2 : 20-hydroxy-20-epi-tingenone CG-3 : 29-hydroxy-3-oxofriedelane CG-4 : 3-oxofriedelan-29-al CG-5 : 3b-acetoxyolean-9(11):12-diene CG-6 : Ourateacatechin (4'-O-mehyl-(-)-epigallocatechin) CG-7 : 9b-benzoyloxy-1a,2a,6b,15-tetraacetoxydihydro-b-agarofuran CG-8 : 9b-benzoyloxy-1a,2a,6b,11-tetraacetoxy-4b-hydroxydihydro-b- agarofuran Figure (​http:​/​​/​www.csirexplorations.com​/​images_et​/​a74_figureNO42.jpg" \t "_blank​) Figure (​http:​/​​/​www.csirexplorations.com​/​images_et​/​a74_figureNO43.jpg" \t "_blank​) The dichloromethane and methanol (1:1) extract of Phyla nodiflora afforded three compounds (cyclohexanone derivatives) PN-1 (51), PN-2A (52) and PN-2B (53). The structures of these compounds were established by comparing with those of the reported spectral data from literature. All the three compounds were first time isolated from this plant. 
PN-1 : Helleridone PN-2A : Helleridone acetate PN-2B : Hellerone diacetate 
Chapter-III 
This chapter describes the screening of the isolated compounds for selected biological activities. All the isolated compounds were tested for antibacterial and antifungal activities. All the plant crude extracts were screened for their anti-inflammatory activity using rat paw edema model (in vivo). The isolated compounds from the active extracts were further screened for in vitro PGE 2 inhibition activity. On the basis of literature reports, the antioxidant and immunomodulatory activities were carried out for the isolated compounds selectively. 
Antibacterial activity: The compounds CG-1 and CG-2 exhibited significant activity against both gram positive (Bacillus subtilis, Staphylococus aureus) and gram negative bacteria (Escherechia coli, Psuedomnas arugenosa) while the compound CG-7 showed moderate activity against P. aeruginosa and S. aureus. Hence the compound CG-2, which has shown more activity, was chosen for the evaluation of minimum inhibitory concentration against all the four and streptomycin was used as standard. Antifungal activity: The compounds EN-1, CG-3 and CG-4 revealed moderate antifungal activity against C. albicans, while PN-1 showed moderate and CG-2 showed good activity against both C. albicans and A. niger. Hence the minimum inhibitory concentration of CG-2 was evaluated by testing at deferent concentrations using nystatin as standard drug. 
Antiinflammatory activity: In vivo: All the plant extracts were tested for their antiinflammatory activity using carrageenan induced rat paw edema model. The percent inhibition edema of extracts were insignificant in the optimal dose levels (250 mg/kg) tested, in comparison to that of indomethacin at a dose of 6 mg/kg, except compound EN-M, which has shown moderate activity in this model. 
In vitro: Selected compounds were tested for their antiinflammatory activity using in-vitro PGE 2 inhibition (COX-2 inhibition) assay. Among the compounds tested compounds EN-4, EN-8 and CG-6 have shown very mild activity at a concentration of 5?g, while EN-3 has shown significant PGE 2 inhibition. Hence, compound EN-3 was further evaluated for PGE 2 inhibition at different molar concentrations and the IC 50 value was compared to that of Celecoxib, a known selective COX-2 inhibitor. 
Antioxidant activity: Compounds were tested for their antioxidant activity using DPPH free radical method, selectively. Of the compounds tested, compounds CG-6 and CG-1 have shown promising antioxidant activity in reducing the DPPH free radical. These compounds were further evaluated for anti oxidant activity at different concentrations and the IC 50 values were found. 
Immunomodulatory activity: The compounds CG-6 and LC-3 were tested for their immunomodulatory activity using mouse spleenocytes method. Cyclosporin A was used as a standard immunosuppressive agent. The results suggested compound CG-6 to act as an immunostimulant where as the compound LC-3 to act as an immunosuppressant.

